{"success":true,"data":{"pressRelease":{"id":"61882","rtpr_id":"nBw5Yfq38a","ticker":"XERS","exchange":"NASDAQ","all_tickers":["XERS"],"title":"Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®","author":"Business Wire","published_at":"2026-06-11T20:39:00.089Z","article_body":"Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark\nOffice for New Patent Covering KEVEYIS(®)\n\nPatent expected to provide intellectual property protection for Keveyis\nthrough 2039\n\nReinforces Xeris’ commitment to the primary periodic paralysis community and\nthe patients who rely on Keveyis\n\nXeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings,\nInc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to\nimproving patient lives by developing and commercializing innovative products\nacross a range of therapies, announced that today the United States Patent and\nTrademark Office (USPTO) has issued a Notice of Allowance with respect to U.S.\nPatent Application No. 17/151,405, entitled “Compositions and Methods of\nUse.” The allowed claims in this application cover the use of the\ncompany’s KEVEYIS(®) (dichlorphenamide) product. The Notice of Allowance\nindicates that the USPTO has determined that the application meets the\nrequirements for patentability and is expected to issue as a U.S. patent\nfollowing the completion of standard administrative steps. Following this\nissuance, the Company will submit the patent to the U.S. Food and Drug\nAdministration (FDA) for listing in the FDA’s publication “Approved Drug\nProducts with Therapeutic Equivalence Evaluations”, commonly known as the\nOrange Book. Assuming that all necessary actions are taken and all maintenance\nfees are paid, this new patent will provide intellectual property protection\nfor KEVEYIS through 2039.\n\n“KEVEYIS is the first FDA-approved therapy for primary periodic paralysis, a\nrare and debilitating condition, and this Notice of Allowance reflects our\nlong-standing commitment to this highly underserved patient community who\ndepend on it,” said John Shannon, CEO of Xeris. “What we do matters. We\nfight for patients every day, and protecting and strengthening the\nintellectual property around KEVEYIS ensures we can continue to deliver this\nimportant therapy and comprehensive support for the primary periodic paralysis\ncommunity for years to come.”\n\nKEVEYIS(®) (dichlorphenamide) is an FDA-approved treatment for primary\nperiodic paralysis (PPP). KEVEYIS is indicated for the treatment of primary\nhyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and\nrelated variants. PPP is a rare genetic condition that affects muscles and\ncauses episodes of muscle weakness and/or temporary paralysis that can be\nprogressive and debilitating. KEVEYIS has been shown to reduce the number,\nseverity, and duration of PPP attacks. For full prescribing information,\nincluding Important Safety Information, please visit www.keveyis.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.keveyis.com&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=www.keveyis.com&index=1&md5=6a15ec6d32f2b59820830f0dde7e8b48)\n.\n\nImportant Safety Information\n\n\n * Contraindications\n\n\n* Hypersensitivity to dichlorphenamide or other sulfonamides\n\n * Concomitant use of KEVEYIS and high-dose aspirin\n\n * Severe pulmonary disease, limiting compensation to metabolic acidosis caused\nby KEVEYIS\n\n * Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy\n\n\n\n\n * Warnings and Precautions\n\n\n* Hypersensitivity/Anaphylaxis/Idiosyncratic Reactions\n\n\n* Fatalities associated with the administration of sulfonamides have occurred\ndue to adverse reactions including Stevens-Johnson syndrome, toxic epidermal\nnecrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and\nother blood dyscrasias.\n\n * Pulmonary involvement can occur in isolation or as part of a systemic\nreaction.\n\n * Discontinue KEVEYIS at the first appearance of skin rash or any sign of\nimmune-mediated or other life-threatening adverse reaction.\n\n\n\n\n\n\n\n * Concomitant Use of Aspirin or Other Salicylates\n\n\n* Carbonic anhydrous inhibitors, including KEVEYIS, can cause metabolic\nacidosis, which can increase the risk of salicylate toxicity.\n\n * Anorexia, tachypnea, lethargy, and coma have been reported with concomitant\nuse of dichlorphenamide and high-dose aspirin.\n\n * Concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Use with\ncaution and carefully monitor in patients receiving low-dose aspirin.\n\n\n\n\n * Hypokalemia\n\n\n* KEVEYIS increases potassium excretion and can cause hypokalemia.\n\n * The risk of hypokalemia is greater when KEVEYIS is used in patients with\nconditions associated with hypokalemia (e.g., adrenocortical excess, renal\ntubular acidosis type 1 and 2), and in patients receiving other drugs that may\ncause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives,\nantifungals, penicillin, and theophylline).\n\n * Baseline and periodic measurements of serum potassium are recommended.\n\n * If hypokalemia develops or persists, consider reducing the dose or\ndiscontinuing KEVEYIS and correction of potassium levels.\n\n\n\n\n * Metabolic Acidosis\n\n\n* KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis.\n\n * Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may\nincrease the severity of acidosis.\n\n * Concomitant use of KEVEYIS in compensated patients with respiratory acidosis,\nsuch as in advanced lung diseases, may lead to respiratory decompensation.\n\n * Baseline and periodic measurements of serum bicarbonate during KEVEYIS\ntreatment are recommended.\n\n * If metabolic acidosis develops or persists, consider reducing the dose or\ndiscontinuing KEVEYIS.\n\n\n\n\n * Falls\n\n\n* KEVEYIS increases the risk of falls; risk is greater in the elderly and with\nhigher doses.\n\n * Consider dose reduction or discontinuation of KEVEYIS in patients who\nexperience falls while treated with KEVEYIS.\n\n\n\n\n * Pregnancy and Lactation\n\n\n* Use during pregnancy only if the potential benefit justifies the potential\nrisk to the fetus. It is not known in humans whether dichlorphenamide is\nexcreted in human milk; exercise caution when administered to a nursing woman.\n\n\n\n\n * Adverse Reactions\n\n\n* The most common adverse reactions seen in clinical trials (incidence ≥ 10%\nand greater than placebo) include paresthesias, cognitive disorder, dysgeusia,\nand confusional state.\n\n\n\n\n * Please see \nFull Prescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fkeveyishcp.com%2Fwp-content%2Fuploads%2F2024%2F06%2Fkeveyis-prescribing-information.pdf&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=Full+Prescribing+Information&index=2&md5=349130f5b5860b2bb342759d331a1685)\n\n.\n\nAbout Xeris\n\nXeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to\nimproving patient lives by developing and commercializing innovative products\nacross a range of therapies. Xeris has three commercially available products:\nRECORLEV(®), for the treatment of endogenous Cushing’s syndrome; GVOKE(®),\na ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and\nKEVEYIS(®), a proven therapy for primary periodic paralysis. Xeris also has a\npipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly\nsubcutaneous injection for hypothyroidism, as well as multiple early-stage\nprograms leveraging Xeris’ technology platforms, XeriSol(®) and\nXeriJect(®), for its partners.\n\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more\ninformation, visit www.xerispharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.xerispharma.com&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=www.xerispharma.com&index=3&md5=a6c94bf19ea24ba32637b44b7e47d979)\n, or follow us on X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2Fxerispharma%3Flang%3Den&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=X&index=4&md5=b4917dd304ad32f8a72876bcbaa2710e)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fxeris-pharmaceuticals%2F&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=LinkedIn&index=5&md5=6c9e8cb3b5ed3b1394e322aae2b7cba0)\n, or Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fxerispharma%2F&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=Instagram&index=6&md5=2b2f2a6aebd3748db6cad8baa5e108e7)\n.\n\nForward-Looking Statements\n\nAny statements in this press release other than statements of historical fact\nare forward-looking statements. Forward-looking statements include, but are\nnot limited to, statements about future expectations, plans, opportunities,\nand prospects for Xeris Biopharma Holdings, Inc., including statements\nregarding, the expected grant and scope of the U.S. patent for Keveyis, the\ncompany’s intention to submit the patent for listing in the FDA’s Orange\nBook, the term of intellectual property protection for Keveyis, the\ncompany’s intention to protect and strengthen its intellectual property\nrights relating to KEVEYIS(®), commitment to protecting the long-term value\nof its assets, the growth potential of its drug products, including KEVEYIS®,\nthe market and therapeutic potential of its products and product candidates,\nand other statements containing the words “will,” “would,”\n“continue,” “expect,” “should,” “anticipate,” and similar\nexpressions, constitute forward-looking statements within the meaning of The\nPrivate Securities Litigation Reform Act of 1995. These forward-looking\nstatements are based on numerous assumptions and assessments made in light of\nXeris’ experience and perception of historical trends, current conditions,\nbusiness strategies, operating environment, future developments, geopolitical\nfactors and other factors it believes appropriate. By their nature,\nforward-looking statements involve known and unknown risks and uncertainties\nbecause they relate to events and depend on circumstances that will occur in\nthe future. The various factors that could cause Xeris’ actual results,\nperformance or achievements, industry results and developments to differ\nmaterially from those expressed in or implied by such forward-looking\nstatements, include, but are not limited to, its financial position and need\nfor financing, including to fund its product development programs or\ncommercialization efforts, whether its products will achieve and maintain\nmarket acceptance in a competitive business environment, its reliance on\nthird-party suppliers, including single-source suppliers, its reliance on\nthird parties to conduct clinical trials, the ability of its product\ncandidates to compete successfully with existing and new drugs, and its\ncollaborators’ ability to protect its intellectual property and proprietary\ntechnology, and general macroeconomic and geopolitical conditions, including\nthe possibility of an economic downturn, changes in governmental priorities\nand resources, announced or implemented tariffs, and market volatility. No\nassurance can be given that such expectations will be realized and persons\nreading this communication are, therefore, cautioned not to place undue\nreliance on these forward-looking statements. Additional risks and information\nabout potential impacts of financial, operational, economic, competitive,\nregulatory, governmental, technological, and other factors that may affect\nXeris can be found in Xeris’ filings, including its most recently filed\nAnnual Report on Form 10-K and subsequent filings with the U.S. Securities and\nExchange Commission, the contents of which are not incorporated by reference\ninto, nor do they form part of, this communication. Forward-looking statements\nin this communication are based on information available to management, as of\nthe date of this communication and, while the Company believes its assumptions\nare reasonable, actual results may differ materially. Subject to any\nobligations under applicable law, the Company does not undertake any\nobligation to update any forward-looking statement whether as a result of new\ninformation, future developments or otherwise, or to conform any\nforward-looking statement to actual results, future events, or to changes in\nexpectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260611817161/en/\n(https://www.businesswire.com/news/home/20260611817161/en/)\n\nInvestor Contact\n\nAllison Wey\n\nSenior Vice President, Investor Relations\n\nawey@xerispharma.com (mailto:awey@xerispharma.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5Yfq38a","title":"Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®","author":"Business Wire","ticker":"XERS","created":"2026-06-11T20:39:00.089Z","tickers":["XERS"],"exchange":"NASDAQ","article_body":"Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark\nOffice for New Patent Covering KEVEYIS(®)\n\nPatent expected to provide intellectual property protection for Keveyis\nthrough 2039\n\nReinforces Xeris’ commitment to the primary periodic paralysis community and\nthe patients who rely on Keveyis\n\nXeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings,\nInc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to\nimproving patient lives by developing and commercializing innovative products\nacross a range of therapies, announced that today the United States Patent and\nTrademark Office (USPTO) has issued a Notice of Allowance with respect to U.S.\nPatent Application No. 17/151,405, entitled “Compositions and Methods of\nUse.” The allowed claims in this application cover the use of the\ncompany’s KEVEYIS(®) (dichlorphenamide) product. The Notice of Allowance\nindicates that the USPTO has determined that the application meets the\nrequirements for patentability and is expected to issue as a U.S. patent\nfollowing the completion of standard administrative steps. Following this\nissuance, the Company will submit the patent to the U.S. Food and Drug\nAdministration (FDA) for listing in the FDA’s publication “Approved Drug\nProducts with Therapeutic Equivalence Evaluations”, commonly known as the\nOrange Book. Assuming that all necessary actions are taken and all maintenance\nfees are paid, this new patent will provide intellectual property protection\nfor KEVEYIS through 2039.\n\n“KEVEYIS is the first FDA-approved therapy for primary periodic paralysis, a\nrare and debilitating condition, and this Notice of Allowance reflects our\nlong-standing commitment to this highly underserved patient community who\ndepend on it,” said John Shannon, CEO of Xeris. “What we do matters. We\nfight for patients every day, and protecting and strengthening the\nintellectual property around KEVEYIS ensures we can continue to deliver this\nimportant therapy and comprehensive support for the primary periodic paralysis\ncommunity for years to come.”\n\nKEVEYIS(®) (dichlorphenamide) is an FDA-approved treatment for primary\nperiodic paralysis (PPP). KEVEYIS is indicated for the treatment of primary\nhyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and\nrelated variants. PPP is a rare genetic condition that affects muscles and\ncauses episodes of muscle weakness and/or temporary paralysis that can be\nprogressive and debilitating. KEVEYIS has been shown to reduce the number,\nseverity, and duration of PPP attacks. For full prescribing information,\nincluding Important Safety Information, please visit www.keveyis.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.keveyis.com&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=www.keveyis.com&index=1&md5=6a15ec6d32f2b59820830f0dde7e8b48)\n.\n\nImportant Safety Information\n\n\n * Contraindications\n\n\n* Hypersensitivity to dichlorphenamide or other sulfonamides\n\n * Concomitant use of KEVEYIS and high-dose aspirin\n\n * Severe pulmonary disease, limiting compensation to metabolic acidosis caused\nby KEVEYIS\n\n * Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy\n\n\n\n\n * Warnings and Precautions\n\n\n* Hypersensitivity/Anaphylaxis/Idiosyncratic Reactions\n\n\n* Fatalities associated with the administration of sulfonamides have occurred\ndue to adverse reactions including Stevens-Johnson syndrome, toxic epidermal\nnecrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and\nother blood dyscrasias.\n\n * Pulmonary involvement can occur in isolation or as part of a systemic\nreaction.\n\n * Discontinue KEVEYIS at the first appearance of skin rash or any sign of\nimmune-mediated or other life-threatening adverse reaction.\n\n\n\n\n\n\n\n * Concomitant Use of Aspirin or Other Salicylates\n\n\n* Carbonic anhydrous inhibitors, including KEVEYIS, can cause metabolic\nacidosis, which can increase the risk of salicylate toxicity.\n\n * Anorexia, tachypnea, lethargy, and coma have been reported with concomitant\nuse of dichlorphenamide and high-dose aspirin.\n\n * Concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Use with\ncaution and carefully monitor in patients receiving low-dose aspirin.\n\n\n\n\n * Hypokalemia\n\n\n* KEVEYIS increases potassium excretion and can cause hypokalemia.\n\n * The risk of hypokalemia is greater when KEVEYIS is used in patients with\nconditions associated with hypokalemia (e.g., adrenocortical excess, renal\ntubular acidosis type 1 and 2), and in patients receiving other drugs that may\ncause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives,\nantifungals, penicillin, and theophylline).\n\n * Baseline and periodic measurements of serum potassium are recommended.\n\n * If hypokalemia develops or persists, consider reducing the dose or\ndiscontinuing KEVEYIS and correction of potassium levels.\n\n\n\n\n * Metabolic Acidosis\n\n\n* KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis.\n\n * Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may\nincrease the severity of acidosis.\n\n * Concomitant use of KEVEYIS in compensated patients with respiratory acidosis,\nsuch as in advanced lung diseases, may lead to respiratory decompensation.\n\n * Baseline and periodic measurements of serum bicarbonate during KEVEYIS\ntreatment are recommended.\n\n * If metabolic acidosis develops or persists, consider reducing the dose or\ndiscontinuing KEVEYIS.\n\n\n\n\n * Falls\n\n\n* KEVEYIS increases the risk of falls; risk is greater in the elderly and with\nhigher doses.\n\n * Consider dose reduction or discontinuation of KEVEYIS in patients who\nexperience falls while treated with KEVEYIS.\n\n\n\n\n * Pregnancy and Lactation\n\n\n* Use during pregnancy only if the potential benefit justifies the potential\nrisk to the fetus. It is not known in humans whether dichlorphenamide is\nexcreted in human milk; exercise caution when administered to a nursing woman.\n\n\n\n\n * Adverse Reactions\n\n\n* The most common adverse reactions seen in clinical trials (incidence ≥ 10%\nand greater than placebo) include paresthesias, cognitive disorder, dysgeusia,\nand confusional state.\n\n\n\n\n * Please see \nFull Prescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fkeveyishcp.com%2Fwp-content%2Fuploads%2F2024%2F06%2Fkeveyis-prescribing-information.pdf&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=Full+Prescribing+Information&index=2&md5=349130f5b5860b2bb342759d331a1685)\n\n.\n\nAbout Xeris\n\nXeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to\nimproving patient lives by developing and commercializing innovative products\nacross a range of therapies. Xeris has three commercially available products:\nRECORLEV(®), for the treatment of endogenous Cushing’s syndrome; GVOKE(®),\na ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and\nKEVEYIS(®), a proven therapy for primary periodic paralysis. Xeris also has a\npipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly\nsubcutaneous injection for hypothyroidism, as well as multiple early-stage\nprograms leveraging Xeris’ technology platforms, XeriSol(®) and\nXeriJect(®), for its partners.\n\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more\ninformation, visit www.xerispharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.xerispharma.com&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=www.xerispharma.com&index=3&md5=a6c94bf19ea24ba32637b44b7e47d979)\n, or follow us on X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2Fxerispharma%3Flang%3Den&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=X&index=4&md5=b4917dd304ad32f8a72876bcbaa2710e)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fxeris-pharmaceuticals%2F&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=LinkedIn&index=5&md5=6c9e8cb3b5ed3b1394e322aae2b7cba0)\n, or Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fxerispharma%2F&esheet=54552141&newsitemid=20260611817161&lan=en-US&anchor=Instagram&index=6&md5=2b2f2a6aebd3748db6cad8baa5e108e7)\n.\n\nForward-Looking Statements\n\nAny statements in this press release other than statements of historical fact\nare forward-looking statements. Forward-looking statements include, but are\nnot limited to, statements about future expectations, plans, opportunities,\nand prospects for Xeris Biopharma Holdings, Inc., including statements\nregarding, the expected grant and scope of the U.S. patent for Keveyis, the\ncompany’s intention to submit the patent for listing in the FDA’s Orange\nBook, the term of intellectual property protection for Keveyis, the\ncompany’s intention to protect and strengthen its intellectual property\nrights relating to KEVEYIS(®), commitment to protecting the long-term value\nof its assets, the growth potential of its drug products, including KEVEYIS®,\nthe market and therapeutic potential of its products and product candidates,\nand other statements containing the words “will,” “would,”\n“continue,” “expect,” “should,” “anticipate,” and similar\nexpressions, constitute forward-looking statements within the meaning of The\nPrivate Securities Litigation Reform Act of 1995. These forward-looking\nstatements are based on numerous assumptions and assessments made in light of\nXeris’ experience and perception of historical trends, current conditions,\nbusiness strategies, operating environment, future developments, geopolitical\nfactors and other factors it believes appropriate. By their nature,\nforward-looking statements involve known and unknown risks and uncertainties\nbecause they relate to events and depend on circumstances that will occur in\nthe future. The various factors that could cause Xeris’ actual results,\nperformance or achievements, industry results and developments to differ\nmaterially from those expressed in or implied by such forward-looking\nstatements, include, but are not limited to, its financial position and need\nfor financing, including to fund its product development programs or\ncommercialization efforts, whether its products will achieve and maintain\nmarket acceptance in a competitive business environment, its reliance on\nthird-party suppliers, including single-source suppliers, its reliance on\nthird parties to conduct clinical trials, the ability of its product\ncandidates to compete successfully with existing and new drugs, and its\ncollaborators’ ability to protect its intellectual property and proprietary\ntechnology, and general macroeconomic and geopolitical conditions, including\nthe possibility of an economic downturn, changes in governmental priorities\nand resources, announced or implemented tariffs, and market volatility. No\nassurance can be given that such expectations will be realized and persons\nreading this communication are, therefore, cautioned not to place undue\nreliance on these forward-looking statements. Additional risks and information\nabout potential impacts of financial, operational, economic, competitive,\nregulatory, governmental, technological, and other factors that may affect\nXeris can be found in Xeris’ filings, including its most recently filed\nAnnual Report on Form 10-K and subsequent filings with the U.S. Securities and\nExchange Commission, the contents of which are not incorporated by reference\ninto, nor do they form part of, this communication. Forward-looking statements\nin this communication are based on information available to management, as of\nthe date of this communication and, while the Company believes its assumptions\nare reasonable, actual results may differ materially. Subject to any\nobligations under applicable law, the Company does not undertake any\nobligation to update any forward-looking statement whether as a result of new\ninformation, future developments or otherwise, or to conform any\nforward-looking statement to actual results, future events, or to changes in\nexpectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260611817161/en/\n(https://www.businesswire.com/news/home/20260611817161/en/)\n\nInvestor Contact\n\nAllison Wey\n\nSenior Vice President, Investor Relations\n\nawey@xerispharma.com (mailto:awey@xerispharma.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-06-11T20:39:00.136756319Z","server_sent_at_ms":1781210340136},"received_at":"2026-06-11T20:39:00.260Z","source_url":"https://www.businesswire.com/news/home/20260611817161/en/"},"analysis":{"id":"51307","press_release_id":"61882","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Xeris Biopharma announced that the USPTO has issued a Notice of Allowance for a new patent covering its lead product KEVEYIS.\n\nThe allowed claims cover the use of dichlorphenamide for primary periodic paralysis, with intellectual property protection expected to extend through 2039.\n\nThe company will submit the patent to the FDA for listing in the Orange Book, reinforcing the competitive moat around its first FDA-approved therapy for this rare condition.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"IP moat strengthened: New patent allowance extends KEVEYIS protection to 2039."},"keyFigures":{"drugName":"KEVEYIS (dichlorphenamide)","customDimensions":{"patent_expiry":"2039","patent_application_number":"17/151,405"}},"quotedText":"protecting and strengthening the intellectual property around KEVEYIS ensures we can continue to deliver this important therapy and comprehensive support for the primary periodic paralysis community for years to come","namedEntities":{"people":[{"name":"John Shannon","role":"CEO"},{"name":"Allison Wey","role":"Senior Vice President, Investor Relations"}],"products":["KEVEYIS","dichlorphenamide","RECORLEV","GVOKE","XP-8121","XeriSol","XeriJect"],"companies":[{"name":"Xeris Pharmaceuticals, Inc.","ticker":"XERS","relationship":"filer"},{"name":"Biopharma Holdings, Inc.","ticker":"XERS","relationship":"parent company"},{"name":"United States Patent and Trademark Office","relationship":"regulatory body"},{"name":"U.S. Food and Drug Administration","relationship":"regulatory body"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Notice of Allowance for a new patent covering the company's lead asset KEVEYIS, extending IP protection through 2039. This is a positive IP milestone that strengthens the competitive moat and revenue visibility for a key product, but it is not a binary regulatory approval or earnings event."},"tickerRelevance":{"others":[],"primary":"XERS"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"patent_allowance","sectorWeight":"biotech_ip","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Xeris Biopharma announced that the USPTO has issued a Notice of Allowance for a new patent covering its lead product KEVEYIS.\n\nThe allowed claims cover the use of dichlorphenamide for primary periodic paralysis, with intellectual property protection expected to extend through 2039.\n\nThe company will submit the patent to the FDA for listing in the Orange Book, reinforcing the competitive moat around its first FDA-approved therapy for this rare condition.","key_figures":{"drugName":"KEVEYIS (dichlorphenamide)","customDimensions":{"patent_expiry":"2039","patent_application_number":"17/151,405"}},"named_entities":{"people":[{"name":"John Shannon","role":"CEO"},{"name":"Allison Wey","role":"Senior Vice President, Investor Relations"}],"products":["KEVEYIS","dichlorphenamide","RECORLEV","GVOKE","XP-8121","XeriSol","XeriJect"],"companies":[{"name":"Xeris Pharmaceuticals, Inc.","ticker":"XERS","relationship":"filer"},{"name":"Biopharma Holdings, Inc.","ticker":"XERS","relationship":"parent company"},{"name":"United States Patent and Trademark Office","relationship":"regulatory body"},{"name":"U.S. Food and Drug Administration","relationship":"regulatory body"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-11T20:39:49.453Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"patent_allowance","sectorWeight":"biotech_ip","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":49183,"modelName":"george-droid-qwen-72b"}}